Romosozumab

Generic Name
Romosozumab
Brand Names
Evenity 210 Mg Dose, Evenity
Drug Type
Biotech
Chemical Formula
-
CAS Number
909395-70-6
Unique Ingredient Identifier
3VHF2ZD92J
Background

Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of...

Indication

Romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatments.

Associated Conditions
Osteoporosis
Associated Therapies
-
Clinical Trials
Related News

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)

Phase 1
Completed
Conditions
Postmenopausal
Osteopenia
Interventions
Drug: Placebo
Drug: Romosozumab
First Posted Date
2013-04-08
Last Posted Date
2023-08-30
Lead Sponsor
Amgen
Target Recruit Count
48
Registration Number
NCT01825785

Transition From Alendronate to Romosozumab (AMG 785)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: Romosozumab
First Posted Date
2012-05-01
Last Posted Date
2019-03-26
Lead Sponsor
Amgen
Target Recruit Count
60
Registration Number
NCT01588509
Locations
🇺🇸

Research Site, Seattle, Washington, United States

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

First Posted Date
2012-04-12
Last Posted Date
2024-08-28
Lead Sponsor
Amgen
Target Recruit Count
7180
Registration Number
NCT01575834
Locations
🇬🇧

Research Site, Reading, United Kingdom

A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women

Phase 1
Completed
Conditions
Osteopenia
Interventions
Drug: Placebo
Drug: Romosozumab
First Posted Date
2010-04-09
Last Posted Date
2019-07-31
Lead Sponsor
Amgen
Target Recruit Count
31
Registration Number
NCT01101061

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

Phase 2
Completed
Conditions
Fracture Healing
Interventions
Drug: Placebo
Drug: Romosozumab
First Posted Date
2010-03-05
Last Posted Date
2022-09-21
Lead Sponsor
Amgen
Target Recruit Count
332
Registration Number
NCT01081678
Locations
🇬🇧

Research Site, Norwich, United Kingdom

A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women

Phase 1
Completed
Conditions
Osteopenia
Interventions
Drug: Placebo
Drug: Romosozumab
First Posted Date
2010-02-01
Last Posted Date
2019-07-05
Lead Sponsor
Amgen
Target Recruit Count
74
Registration Number
NCT01059435

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

Phase 1
Completed
Conditions
Osteopenia
Interventions
Drug: Placebo
Drug: Romosozumab
First Posted Date
2009-08-03
Last Posted Date
2019-07-05
Lead Sponsor
Amgen
Target Recruit Count
24
Registration Number
NCT00950950

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

First Posted Date
2009-05-11
Last Posted Date
2022-09-22
Lead Sponsor
Amgen
Target Recruit Count
419
Registration Number
NCT00896532
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy